New drug duo takes on hard-to-treat lymphoma
NCT ID NCT05685173
First seen Mar 31, 2026 · Last updated May 19, 2026 · Updated 12 times
Summary
This early-stage study tests a new drug (REGN5837) combined with another drug (odronextamab) for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior treatments. The first part finds a safe dose, and the second part checks how well the combination works. About 107 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKINS LYMPHOMA (B-NHL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam University Medical Centre, location AMC
RECRUITINGAmsterdam, 1100AZ, Netherlands
-
CHU de Bordeaux
RECRUITINGTalence, New Aquitaine, 33404, France
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Erasmus Medical Center Rotterdam
RECRUITINGRotterdam, South Holland, 3015, Netherlands
-
Gustave Roussy
RECRUITINGVillejuif, Île-de-France Region, 94800, France
-
Harvard Medical School - Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Hopital Saint Louis
RECRUITINGParis, 75010, France
-
Hospital Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
NYU Langone Health Perlmutter Cancer Center
RECRUITINGNew York, New York, 10016, United States
-
Norton Cancer Institute
RECRUITINGLouisville, Kentucky, 40207, United States
-
Royal Cornwall Hospitals NHS Trust
RECRUITINGTruro, Cornwall, TR1 3LJ, United Kingdom
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
Southampton General Hospital
RECRUITINGSouthampton, Hampshire, SO16 6YD, United Kingdom
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
-
UT Southwestern
RECRUITINGDallas, Texas, 75390, United States
-
University Hospital and Research Institute
RECRUITINGMadrid, 28041, Spain
-
University of California Los Angeles (UCLA) Medical Center
RECRUITINGSanta Monica, California, 90404, United States
-
Western General Hospital
RECRUITINGEdinburgh, Scotland, EH4 2XU, United Kingdom
Conditions
Explore the condition pages connected to this study.